We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

zaterdag 17 juni 2017

The Lancet: [Comment] Simvastatin and cognition in multiple sclerosis

[Comment] Simvastatin and cognition in multiple sclerosis
Few treatment options are available for patients with progressive multiple sclerosis,1 in whom anti-inflammatory drugs have little effect and for whom clinical manifestations, such as cognitive impairment and neuropsychiatric dysfunction, have a dramatic effect on quality of life. Preservation of functional and social independence are perhaps the main therapeutic goals in these patients.
Read more

[Articles] Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis
NfL in plasma shows promise as a potential prognostic blood biomarker of disease onset and progression in Huntington's disease.
Read more

[Comment] Potential biomarker breakthrough for Huntington's disease
Huntington's disease, with a single genetic cause and correlation between age of onset and length of the CAG repeat in the huntingtin gene (HTT), has long served as a model for neurodegenerative diseases. Predictive genetic testing has made it possible to define the natural history of the disease and to show that regional brain atrophy, especially of the striatum, begins many years before diagnosable motor onset and progresses steadily through the premanifest and manifest periods.1–3 Structural neuroimaging enables excellent tracking of progressive atrophy; however, it requires an expensive apparatus and does not provide a direct chemical reflection of brain injury.
Read more

[Articles] Prediction of cognition in Parkinson's disease with a clinical–genetic score: a longitudinal analysis of nine cohorts
Our predictive algorithm provides a potential test for future cognitive health or impairment in patients with Parkinson's disease. This model could improve trials of cognitive interventions and inform on prognosis.
Read more

[Comment] A new tool to identify patients with Parkinson's disease at increased risk of dementia
Many patients with Parkinson's disease develop dementia; some patients develop dementia within the first 5 years after diagnosis of Parkinson's disease, whereas others remain free of dementia for more than 10–15 years after diagnosis.1 Identification of individuals at the highest risk of early dementia is important for the development of targeted intervention strategies for the primary prevention of dementia and for enabling future planning for patients, carers, and delivery of true personalised medicine.
Read more